Martin Auster analyst RAYMOND JAMES

Currently out of the existing stock ratings of Martin Auster, 145 are a BUY (73.6%), 11 are a SELL (5.58%), 41 are a HOLD (20.81%).

Martin Auster

Work Performance Price Targets & Ratings Chart

Analyst Martin Auster, currently employed at RAYMOND JAMES, has had 72.04% of price targets met with an average potential upside of 33.62%, reached in 276 days on average.

Martin Auster has documented 392 price targets and ratings displayed on 44 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on ALNY, Alnylam Pharmaceuticals at 30-Oct-2026.

Wall Street Analyst Martin Auster

Analyst best performing recommendations are on FTSV (FORTY SEVEN).
The best stock recommendation documented was for ALNY (ALNYLAM PHARMACEUTICALS) on 7/29/2025. The price target of $370 was fulfilled within 2 days with a profit of $39.45 (11.93%), with a performance score of 59.67.

Average potential price target upside

ALXN Alexion Pharmaceuticals ALXO Alx Oncology Holdings ANAB AnaptysBio ARNA Arena Pharmaceuticals BMRN Biomarin Pharmaceutical ESPR Esperion Therapeutics ETTX Entasis Therapeutics Holdings INSM Insmed MYOK MyoKardia PTCT PTC Therapeutics RARE Ultragenyx SLDB Solid Biosciences LLC SRPT Sarepta Therapeutics STOK Stoke Therapeutics UTHR United Therapeutics XLRN Acceleron Pharma OBSV ObsEva SA ONCE Spark Therapeutics GLTO Galecto RXDX Prometheus Biosciences INBX Inhibrx CVAC CureVac NV KURA Kura Oncology NTLA Intellia Therapeutics IRWD Ironwood Pharmaceuticals DYN Dyne Therapeutics ALNY Alnylam Pharmaceuticals BBIO BridgeBio Pharma SRRK Scholar Rock Holding Corp ASND Ascendis Pharma AS EWTX Edgewise Therapeutics IRON Disc Medicine SEPN Septerna PDSB PDS Biotechnology Corp FTSV Forty Seven

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 28-Jul-2017

$205

5 years 6 months 16 days ago
(05-May-2021)

3/5 (60%)

$35.09 (20.65%)

938

Hold Since 03-May-2021

$173

$156

5 years 6 months 18 days ago
(03-May-2021)

18/29 (62.07%)

$2.73 (1.60%)

667

Buy Since 08-Feb-2018

$166

$179

5 years 9 months 17 days ago
(04-Feb-2021)

21/21 (100%)

$10.41 (6.69%)

711

Hold Since 04-Feb-2021

$190

$194

5 years 9 months 17 days ago
(04-Feb-2021)

13/15 (86.67%)

$34.41 (22.12%)

458

Buy Since 06-Sep-2019

$175

$165

5 years 9 months 17 days ago
(04-Feb-2021)

3/3 (100%)

$19.41 (12.48%)

397

Show more analysts

Stocks Martin Auster covered previously. Scores are shown for active stocks only.

AL Air Lease CV FLXN Flexion Therapeutics FULC Fulcrum Therapeutics GL Globe Life QURE Uniqure NV RNA Avidity Biosciences SPRB Spruce Biosciences

Please expand the browser size to see the chart

Which stock is Martin Auster most bullish on?

Potential upside of $167.18 has been obtained for ALNY (ALNYLAM PHARMACEUTICALS)

Which stock is Martin Auster most reserved on?

Potential downside of -$0 has been obtained for BBIO (BRIDGEBIO PHARMA)

What Year was the first public recommendation made by Martin Auster?

On 2017
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?